Key TakeawaysUnitedHealth Group and Amedisys agreed to extend the deadline to complete their $3.3 billion merger. The deal had been expected to be completed this week, but federal and state regulators moved to block it, and the challenge is currently before a Maryland court.The deal's new deadline is 10 days following the court's ruling or Dec. 31, 2025, whichever comes first. UnitedHealth Group (UNH) and Amedisys (AMED) agreed to extend the deadline to complete their $3.3 billion merger, after the U.S. Dep ...

Amedisys Inc AMED shares are trading higher on Friday after the company announced it extended its merger deadline with UnitedHealth Group Incorporated UNH.In an exchange filing, the companies entered into a waiver agreement, further advancing their merger deal, originally announced on June 26, 2023.Under the terms of the agreement, Merger Sub, a wholly owned subsidiary of UnitedHealth, will merge with Amedisys, with Amedisys continuing to operate as a subsidiary of UnitedHealth Group.The companies have agre ...

Core Insights - Amedisys, Inc. reported adjusted earnings per share (EPS) of $1.00 for Q3 2024, a 2% increase year over year, but missed the Zacks Consensus Estimate by 12.3% [1] - The company's net service revenues reached $587.7 million, reflecting a 5.7% year-over-year growth, but also fell short of the Zacks Consensus Estimate by 0.1% [3] - The impending merger with UnitedHealth Group's Optum is expected to close in the second half of 2024, aiming to enhance value-based care delivery [10] Financial Performance - The GAAP EPS was reported at 51 cents, down from 79 cents in the same period of 2023 [1] - Gross profit increased by 2.2% to $250.1 million, while gross margin decreased by 142 basis points to 42.6% due to an 8.3% rise in service costs [6] - Selling, General and Administrative (SG&A) expenses rose by 4.4% to $134.8 million, while adjusted operating profit was $58.5 million, a 0.4% increase year over year [7] Segment Analysis - Home Health division revenues totaled $372.1 million, up 5.8% year over year, with Medicare revenues decreasing by 2.7% to $212.1 million, while non-Medicare revenues increased by 19.7% to $160 million [4] - Hospice division revenues were $207.9 million, a 3.8% increase year over year, with Medicare revenues rising by 4.7% to $197.8 million, but non-Medicare revenues fell by 10.6% to $10.1 million [4] - The High Acuity Care segment reported revenues of $7.7 million, up from $4.4 million in the previous year [5] Liquidity and Cash Position - Amedisys ended Q3 2024 with cash and cash equivalents of $245.4 million, an increase from $149.9 million at the end of Q2 2024 [8] - Cumulative net cash provided by operating activities was $151.4 million, compared to $76.9 million a year ago [9] Merger Developments - The merger with UnitedHealth Group involves the sale of certain Amedisys home health care centers and UnitedHealth Group care centers to VCG Luna, LLC, contingent on the merger's successful closing [11]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share AMED The NASDAQ Global Select Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ...

For the quarter ended September 2024, Amedisys (AMED) reported revenue of $587.67 million, up 5.7% over the same period last year. EPS came in at $1.00, compared to $0.98 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $588.13 million, representing a surprise of -0.08%. The company delivered an EPS surprise of -12.28%, with the consensus EPS estimate being $1.14.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ho ...

Amedisys (AMED) came out with quarterly earnings of $1 per share, missing the Zacks Consensus Estimate of $1.14 per share. This compares to earnings of $0.98 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -12.28%. A quarter ago, it was expected that this home health care and hospice services provider would post earnings of $1.22 per share when it actually produced earnings of $1.32, delivering a surprise of 8.20%.Over the las ...

Exhibit 99.1 AMEDISYS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS BATON ROUGE, Louisiana (November 6, 2024) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and ninemonth periods ended September 30, 2024. Three-Month Periods Ended September 30, 2024 and 2023 • Net service revenue increased $31.5 million to $587.7 million compared to $556.2 million in 2023. • Net income attributable to Amedisys, Inc. of $16.9 million, which is inclusive of merger-related expenses totaling $ ...

BATON ROUGE, La., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2024. Three-Month Periods Ended September 30, 2024 and 2023 Net service revenue increased $31.5 million to $587.7 million compared to $556.2 million in 2023.Net income attributable to Amedisys, Inc. of $16.9 million, which is inclusive of merger-related expenses totaling $16.7 million ($16.7 million, net of tax) compared to net incom ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Amedisys (AMED) . This company, which is in the Zacks Medical - Outpatient and Home Healthcare industry, shows potential for another earnings beat.This home health care and hospice services provider has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise f ...

Investors interested in stocks from the Medical - Outpatient and Home Healthcare sector have probably already heard of Amedisys (AMED) and Chemed (CHE) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision ...